OVA Peptide(257-264) TFA
Based on 26 publication(s) in Google Scholar
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.67%
- CAS No.: 1262751-08-5
- Formule: C47H75F3N10O15
- Masse moléculaire:1077.15
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P0286
OVA Peptide (323-339)Kb-Restricted Peptide Epitope -
HY-P1489
OVA Peptide(257-264)Octamer Peptide -
HY-W250978
OvalbuminsAllergen -
HY-135748
Polyinosinic-polycytidylic acid sodiumTLR3 Agonist -
HY-13259
MG-132Proteasome Inhibitor -
HY-P7077
IL-2 Protein, Mouse -
HY-K1023
PBS Powder (1 L of 1×) -
HY-P5411
OVA-T4 PeptideOT-I TCR Ligand -
HY-100415
UKI-1uPA Inhibitor
Publications Citing Use of MedChemExpress (MCE) OVA Peptide(257-264) TFA
More- Signal Transduct Target Ther. 2026 Jul 24;11(1):290.
- Signal Transduct Target Ther. 2026 Apr 28;11(1):156. [Abstract]
- Cancer Cell. 2026 Jun 11:S1535-6108(26)00257-6. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cancer Cell. 2025 Sep 8;43(9):1758-1775.e8. [Abstract]
- Cell. 2026 Sep 17;189(19):6012-6023.e5.
- Cell. 2026 Jun 25;189(13):3922-3939.e20. [Abstract]
- Immunity. 2026 Jul 3:S1074-7613(26)00253-0.
- Nat Commun. 2025 Sep 2;16(1):8181. [Abstract]
- Mol Cell. 2024 Mar 21;84(6):1120-1138.e8. [Abstract]
- Adv Sci (Weinh). 2026 Mar 13:e18525. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2404756. [Abstract]
- Biomaterials. 2026 Jun:329:123925. [Abstract]
- J Control Release. 2026 Jul 10:395:115032. [Abstract]
- J Control Release. 2026 Jul 18:398:115176.
- Cell Death Dis. 2025 Jun 20;16(1):462. [Abstract]
- Cell Commun Signal. 2024 Aug 27;22(1):413. [Abstract]
- Mol Ther. 2026 Jun 2:S1525-0016(26)00470-3. [Abstract]
- J Med Chem. 2026 Apr 23;69(8):9603-9614. [Abstract]
- J Med Chem. 2026 Feb 26;69(4):4900-4912. [Abstract]
- OncoImmunology. 2022 Feb 9;11(1):2034257. [Abstract]
- Nutrients. 2024 Oct 22;16(21):3577. [Abstract]
- Pathol Res Pract. 2025 Jun:270:155975. [Abstract]
- bioRxiv. 2026 Apr 28.
- BIO Web of Conferences. 2025 Jul 2.
- bioRxiv. 2023 Jan 31.
Customer Validation & Images
-
Flow Cytometry
-
Cell Imaging/Staining
Activité biologique
Description
In Vitro
TAP1-I- and C57BL/6 macrophages may process Crl-OVA and full-length OVA in different cellular compartments and that the protein context of the OVA Peptide(257-264) epitope influences the extent of TAP-independent processing for MHC class I presentation. OVA Peptide(257-264) epitope is presented with a differential dependence on the TAP transporter depending on the protein context of the OVA epitope: OVA Peptide(257-264) contained within the MBPCrl-OVA or Crl-OVA bacterial fusion proteins is presented with little dependence on the TAP transporter, while OVA Peptide(257-264) contained within full-length ovalbumin is largely dependent on the TAP transporter, regardless of whether recombinant OVA is expressed in bacteria or the native protein is coupled to polystyrene beads[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
CAS No. 1262751-08-5
-
Appearance Solid
-
Masse moléculaire 1077.15
-
Formule C47H75F3N10O15
-
Color White to off-white
-
Sequence
Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu
-
Sequence Shortening
SIINFEKL
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
-
Signal Transduct Target Ther
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. [Abstract]2026 Apr 28;11(1):156. PMID: 42045172 -
Cancer Cell
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. [Abstract]2026 Jun 11:S1535-6108(26)00257-6. PMID: 42276047 -
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cancer Cell
DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. [Abstract]2025 Sep 8;43(9):1758-1775.e8. PMID: 40816293 -
-
Cell
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. [Abstract]2026 Jun 25;189(13):3922-3939.e20. PMID: 42102817 -
-
Nat Commun
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. [Abstract]2025 Sep 2;16(1):8181. PMID: 40897711 -
Mol Cell
2024 Mar 21;84(6):1120-1138.e8. PMID: 38377992 -
Adv Sci (Weinh)
Context-Dependent Role of GDF15: GDF15+ Tumor-Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis. [Abstract]2026 Mar 13:e18525. PMID: 41824793 -
Adv Sci (Weinh)
ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. [Abstract]2024 Dec;11(45):e2404756. PMID: 39377228 -
Biomaterials
2026 Jun:329:123925. PMID: 41453350 -
J Control Release
STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves. [Abstract]2026 Jul 10:395:115032. PMID: 42155600 -
-
Cell Death Dis
ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma. [Abstract]2025 Jun 20;16(1):462. PMID: 40541964 -
Cell Commun Signal
Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2. [Abstract]2024 Aug 27;22(1):413. PMID: 39192276 -
Mol Ther
Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness. [Abstract]2026 Jun 2:S1525-0016(26)00470-3. PMID: 42231576 -
J Med Chem
Dual-Functional Anti-SIRPα-cGAMP Conjugate Reprograms the Tumor Immune Microenvironment and Enhances Antitumor Immunity. [Abstract]2026 Apr 23;69(8):9603-9614. PMID: 41918375 -
J Med Chem
Modulation of Tumor Microenvironment via Antibody Mediated Precision Delivery of CpG to Myeloid Cell. [Abstract]2026 Feb 26;69(4):4900-4912. PMID: 41649040 -
OncoImmunology
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer. [Abstract]2022 Feb 9;11(1):2034257. PMID: 35154907 -
Nutrients
Effect of Nicotinamide Riboside Against the Exhaustion of CD8+ T Cells via Alleviating Mitochondrial Dysfunction. [Abstract]2024 Oct 22;16(21):3577. PMID: 39519411 -
Pathol Res Pract
SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion. [Abstract]2025 Jun:270:155975. PMID: 40228401 -
-
OVA Peptide(257-264) TFA purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
OT-1 CD8+ T cells were stimulated with OVA Peptide(257-264) TFA (SIINFEKL peptide) (1 ug/mL; 24-48 h) and sampled for CFSE detection via flow cytometry.
OVA Peptide(257-264) TFA purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
B16F10-FLuc cells were pre-treated with/without OVA Peptide(257-264) TFA (SIINFEKL peptide) (25 nM; 2 h) and then co-cultured with OT-1 CD8+ T cells for 4 h. Luminescence was measured by mixing 50 μL of supernatant with 100 μL of luciferase substrate.
-
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (116.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (4.64 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9284 mL | 4.6419 mL | 9.2838 mL | 23.2094 mL |
| DMSO | 5 mM | 0.1857 mL | 0.9284 mL | 1.8568 mL | 4.6419 mL |
| 10 mM | 0.0928 mL | 0.4642 mL | 0.9284 mL | 2.3209 mL | |
| 15 mM | 0.0619 mL | 0.3095 mL | 0.6189 mL | 1.5473 mL | |
| 20 mM | 0.0464 mL | 0.2321 mL | 0.4642 mL | 1.1605 mL | |
| 25 mM | 0.0371 mL | 0.1857 mL | 0.3714 mL | 0.9284 mL | |
| 30 mM | 0.0309 mL | 0.1547 mL | 0.3095 mL | 0.7736 mL | |
| 40 mM | 0.0232 mL | 0.1160 mL | 0.2321 mL | 0.5802 mL | |
| 50 mM | 0.0186 mL | 0.0928 mL | 0.1857 mL | 0.4642 mL | |
| 60 mM | 0.0155 mL | 0.0774 mL | 0.1547 mL | 0.3868 mL | |
| 80 mM | 0.0116 mL | 0.0580 mL | 0.1160 mL | 0.2901 mL | |
| 100 mM | 0.0093 mL | 0.0464 mL | 0.0928 mL | 0.2321 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
OVA Peptide(257-264) TFA Related Classifications
HY-P1489A Related Classifications
Powered by Bioz